8 documents found, page 1 of 1
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA...
Lanièce Delaunay, Charlotte; Martínez-Baz, Iván; Sève, Noémie; Domegan, Lisa; Mazagatos, Clara; Buda, Silke; Meijer, Adam; Kislaya, IrinaBackground: Scarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. Aim: We aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases. Methods: This European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SAR...
Health and economic impact of seasonal influenza mass vaccination strategies in...
Sandmann, Frank; van Leeuwen, Edwin; Bernard-Stoecklin, Sibylle; Casado, Itziar; Castilla, Jesús; Domegan, Lisa; Gherasim, Alin; Hooiveld, MariëtteIntroduction: Despite seasonal influenza vaccination programmes in most countries targeting individuals aged ≥ 65 (or ≥ 55) years and high risk-groups, significant disease burden remains. We explored the impact and cost-effectiveness of 27 vaccination programmes targeting the elderly and/or children in eight European settings (n = 205.8 million). Methods: We used an age-structured dynamic-transmission model to ...
Effectiveness of complete primary vaccination against COVID-19 at primary care ...
Kissling, Esther; Hooiveld, Mariëtte; Martínez-Baz, Iván; Mazagatos, Clara; William, Naoma; Vilcu, Ana-Maria; Kooijman, Marjolein N.; Ilić, MajaIntroduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by ...
Establishing a novel European hospital surveillance platform in response to a n...
Ladbury, Georgia; Hamilton, Mark; Harvey, Ciaran; Mutch, Heather; McMahon, James; Mokogwu, Damilola; Sadiq, Fatima; Young, Johanna; Wallace, LesleyBackground: The first signal of a new infection is often severe cases presenting at hospital. Enhanced surveillance of these cases is critical to learning more about disease epidemiology and patient outcomes, but nationallevel surveillance can lack power to draw conclusions. In response to the emergence of SARS-CoV-2, the Influenza-Monitoring Vaccine Effectiveness (I-MOVE) network, founded in 2007, expanded to ...
Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 6...
Kissling, Esther; Hooiveld, Mariette; Sandonis Martín, Virginia; Martínez-Baz, Iván; William, Naoma; Vilcu, Ana-Maria; Mazagatos, Clara; Domegan, LisaThe I-MOVE-COVID-19 network collates epidemiological and clinical information on patients with coronavirus disease (COVID-19), including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virological characterisation in 11 European countries [1]. One component of I-MOVE-COVID-19 is the multicentre vaccine effectiveness (VE) study at primary care/outpatient level in nine European study sites in eight c...
Vaccine effectiveness against influenza A(H3N2) and B among laboratory‐confirme...
Rose, Angela M.C.; Kissling, Esther; Gherasim, Alin; Casado, Itziar; Bella, Antonino; Launay, Odile; Lazăr, Mihaela; Marbus, Sierk; Kuliese, MonikaBackground: Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2017-18, predominated by influenza B. WHO-recommended, trivalent vaccine components were lineage-mismatched for B. The I-MOVE hospital network measured 2017-18 seasonal influenza vaccine effectiveness (IVE) against influenza A(H3N2) and B among hospitalised patients (≥65 years) in Europe. Methods: Following the same generic pro...
Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2)...
Rondy, Marc; Gherasim, Alin; Casado, Itziar; Launay, Odile; Rizzo, Caterina; Pitigoi, Daniela; Mickiene, Aukse; Marbus, Sierk D; Machado, AusendaIn a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could...
2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A...
Rondy, Marc; Larrauri, Amparo; Casado, Itziar; Alfonsi, Valeria; Pitigoi, Daniela; Launay, Odile; Syrjänen, Ritva K; Gefenaite, Giedre; Machado, AusendaWe conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised influenza A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset of symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination and underlying...